Veracyte Inc. (12V)
XMUN 
Summary
12V Chart
All You Need to Know About Veracyte (VCYT) Rating Upgrade to Strong Buy
Veracyte (VCYT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Veracyte Stock Surges 117% in a Year: What's Driving the Rally?
VCYT's 117% stock surge is driven by durable growth plans, Afirma demand, TrueMRD progress, international IVD efforts and a debt-free balance sheet.
Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Veracyte Inc. (12V) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Veracyte Inc. ever had a stock split?
Veracyte Inc. Profile
| Biotechnology Industry | Healthcare Sector | Marc Stapley CEO | XMUN Exchange | US92337F1075 ISIN |
| US Country | 755 Employees | - Last Dividend | - Last Split | 30 Oct 2013 IPO Date |
Overview
Veracyte, Inc. is a recognized diagnostics company with a presence both in the United States and internationally. The firm has carved out a niche for itself in the field of genomic diagnostics, focusing on providing solutions that accurately diagnose various forms of cancer and other serious diseases. Veracyte leverages advanced genomic technology to offer a range of classifiers and assays designed to improve patient outcomes by making early and accurate diagnoses possible. Originally founded under the name Calderome, Inc., the company underwent a name change to Veracyte, Inc. in March 2008. Since its incorporation in 2006, Veracyte has established its headquarters in South San Francisco, California, symbolizing a hub of innovation and medical advancement in the diagnostics arena.
Products and Services
- Afirma Genomic Sequencing Classifier: Designed for the analysis of cancerous thyroid nodules, this classifier aids in distinguishing between benign and malignant tumors, thereby helping in the decision-making process for whether or not surgery is necessary.
- Decipher Prostate Biopsy and Radical Prostatectomy: These tools are aimed at diagnosing prostate cancer by evaluating the genetic markers of prostate biopsy samples or tissues removed during a prostatectomy, contributing to personalized treatment planning.
- Prosigna Breast Cancer Assay: Focused on breast cancer diagnosis, this assay provides an assessment of the risk of recurrence, leveraging genomic information to guide treatment decisions.
- Percepta Nasal Swab Test: A novel approach for lung cancer diagnosis, this test uses a simple nasal swab to collect cells, which are then analyzed to detect genetic markers associated with lung cancer, offering a non-invasive screening option.
- Envisia Genomic Classifier: This test is designed for the diagnosis of interstitial lung diseases, including idiopathic pulmonary fibrosis, through the genomic profiling of lung tissue samples, helping differentiate between various types of lung fibrosis without the need for surgical biopsy.
- Developmental Projects: Veracyte is currently developing additional diagnostic tools such as the Envisia Classifier, which further advances its capabilities in lung disease diagnosis, the nCounter analysis system for broader genomic profiling needs across various diseases, and LymphMark, a test aimed at the subtyping of lymphoma, to enrich its product portfolio and address unmet medical needs.
